

## PATENT SPECIFICATION

(11) 1 489 280

1 489 280

- (21) Application No. 2247/75 (22) Filed 17 Jan. 1975  
 (31) Convention Application No. 49/012 184  
 (32) Filed 31 Jan. 1974  
 (31) Convention Application No. 49/055 000  
 (32) Filed 18 May 1974  
 (31) Convention Application No. 49/061 853  
 (32) Filed 3 June 1974  
 (31) Convention Application No. 49/129 521  
 (32) Filed 12 Nov. 1974  
 (31) Convention Application No. 49/135 184  
 (32) Filed 26 Nov. 1974 in  
 (33) Japan (JA)  
 (44) Complete Specification published 19 Oct. 1977  
 (51) INT CL<sup>1</sup> C07D 231/56; A61K 31/415; C07D 401/06, 403/06,  
 413/06  
 (52) Index at acceptance  
 C2C 1341 1344 1403 1532 1562 1626 200 213 215 220 226  
 22Y 246 250 251 252 255 25Y 28X 29X 29Y 30Y 311  
 313 314 31Y 321 322 323 32Y 337 351 352 360 361  
 36Y 386 43X 455 456 45X 45Y 509 50Y 620 623 635  
 650 652 698 761 763 777 77Y 790 79Y NL TP WD  
 ZD




## (54) INDAZOLE DERIVATIVES

(71) We, CHUGAI SEIYAKU KABUSHIKI KAISHA, a Japanese body corporate of No. 5-1, 5-chome, Ukima, Kita-ku, Tokyo, Japan, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to indazole derivatives.


The invention provides indazole derivatives having the formula:



wherein X is a hydrogen atom, a halogen atom or lower alkyl group; each of R and R' is a hydrogen atom, a lower alkyl group or a lower alkenyl group, or R and R', together with the nitrogen atom to which they are attached, form an unsubstituted or substituted heterocyclic ring; and n is 1, 2 or 3.


The indazole derivatives of the formula (I) are novel compounds having tranquilizing activity, antidepressive activity, anti-inflammatory activity, circulatory activity, etc., and are useful as medicines. Thus, the invention also provides a pharmaceutical composition comprising, as active ingredient, an indazole derivative of the invention and a pharmaceutically-acceptable diluent or carrier therefor.

Examples of indazole derivatives of the invention are: (1) indazole derivatives having the formula:




wherein X is as defined above with respect to formula (I); each of R and R' is a lower alkyl group or an allyl group, or R and R', together with the nitrogen atom to which they are attached, form a heterocyclic ring optionally substituted by a lower alkyl group; and n is 2 or 3;

(2) indazole derivatives having the general formula:




wherein X is as defined above with respect to formula (I); and each of R and R' is a lower alkyl group, or R and R', together with the nitrogen atom to which they are attached, form an unsubstituted or substituted heterocyclic ring;

(3) indazole derivatives having the formula




where X and n are as defined above with respect to formula (I).

(4) indazole derivatives having the formula:



wherein X and n are as defined above with respect to formula (I);


(5) indazole derivatives having the formula:




wherein X is defined above with respect to formula (I); each of R and R' is a hydrogen atom or a lower alkyl group, or R and R', together with the nitrogen atom to which they are attached, form a heterocyclic ring optionally substituted by a phenyl group; and n is 2 or 3.

According to the invention, the indazole derivatives of the invention can be prepared as follows:

(1) indazole derivatives of formula (II) can be prepared by reacting a compound having the formula:




wherein X is as defined above with respect to formula (I), with a compound having the formula:



wherein X' is a halogen atom, and R, R' and n are as defined above with respect to formula (II);

(2) indazole derivatives of formula (III) can be prepared by reacting a compound having the formula:




wherein X is as defined above with respect to formula (I), with a compound having the formula:




wherein R and R' are as defined above with respect to formula (III);

(3) indazole derivatives of formula (IV) can be prepared by reacting a compound having the formula:




wherein X is as defined above with respect to formula (I), with a compound having the formula:




wherein X' is a halogen atom and n is as defined above with respect to formula (I);

(4) indazole derivatives of formula (V) can be prepared by reacting a compound having the formula:



where X and n are as defined above with respect to formula (I), with hydrazine;

(5) indazole derivatives of formula (VI) can be prepared by reducing a compound having the formula:



wherein n' is n-1, n being as defined above with respect to formula (VI), X is as defined above with respect to formula (I), and R and R' are as defined above with respect to formula (VI).


In the formulae (I), (II), (III), (VI), (VIII), (X) and (XIV), R and R' may be the same or different. In formulae (I), (III) and (X), when R and R' taken together form a substituted heterocyclic ring, the substituent may be, for example, a methyl group or a phenyl group. In formulae (II) and (VIII), when R and R' taken together form a substituted heterocyclic ring, the substituent may be, for example, a methyl group.

As used herein, a lower alkyl group is one containing from 1 to 4 carbon atoms (e.g. a methyl group, an ethyl group or an n-butyl group), and a lower alkenyl group is one containing 2, 3 or 4 carbon atoms (e.g. an alkyl group).

The heterocyclic ring is exemplified by a morpholino group, a piperidino group, a piperazino group, a pyrrolidino group, a 1,2,3,6-tetrahydropyridino group, and a phthalimido group.

The compound of the formula (VII) used in the process (1) as a starting material can be obtained by diazonizing a 2-aminobenzophenone derivative, ring-closing the diazonized product with sodium sulfite and treating the product with stannous chloride (Berichte der Deutschen Chemischen Gesellschaft, vol. 29, p. 1255 (1896)).

The compound of the formula (XIV) used in the process (5) as a starting compound is a novel compound and is prepared by, for example, the following reaction:



wherein R, R' and n' are as defined above with respect to formula (VI); X is as defined above with respect to formula (I); X' is a halogen atom; and R'' is a lower alkyl group.

The compound of the formula (IX) used in the process (2) as a starting compound is prepared by reacting the compound of formula (VII) with formaldehyde and industrially without separation of this intermediate it can be immediately reacted with the amine of the formula (X).

In the practice of the process (1) of the invention the reaction of the compound of the formula (VII) with the compound of the formula (VIII) is carried out in a suitable organic solvent, for example dimethylformamide, toluene, methanol, ethanol and at a temperature of room temperature or above generally for 10—90 minutes.

It is preferable to use an excessive molar amount of the compound of the formula (VIII) in comparison with the compound of the formula (VII), and in order to carry out the reaction smoothly and increase the yield, it is favorable to use a condensating agent, for example, an equimolar amount or an excessive molar amount of sodium hydride, sodium alcoholate, sodium amide or sodium hydroxide. In the case wherein the starting compound of the formula (VIII) is in the form of hydrochloric acid salt, it is used after the conversion to a free amine with the use of base such as sodium hydroxide and dissolving the free amine in a solvent such as toluene.

And in the industrial practice of this process, if a quaternary ammonium salt such as triethylbenzylammonium chloride is used as a phase transfer catalysis, water can be used as a solvent.

In the practice of the process (5), the reduction reaction of the compound of the formula (XIV) is carried out at a temperature of room temperature or above; preferably reflux temperature of the reaction mixture, for 10—60 minutes after dissolving the compound (XIV) in a suitable solvent such as tetrahydrofuran or diethyl ether and adding an equimolar or excessive molar amount of a usual reducing agent such as lithium aluminum hydride to the solution.

In the practice of the process (2), the compound of the formula (IX) is reacted with the amine of the formula (X) in a suitable solvent, for example ethanol or methanol. The reaction is carried out at room temperature or a temperature higher than room temperature, preferably reflux temperature of the reaction mixture, for 1—5 hours. Preferably the amine of the formula (X) is used in the equimolar or an excessive molar amount in comparison with the amount of the compound of the formula (IX). An appropriate catalyst used as sodium hydroxide or potassium hydroxide may be used. When the desired compound is obtained from the compound of the formula (VII) through the compound of the formula

(IX), the reaction can be carried out in a one-step procedure by adding formaldehyde and amine simultaneously to the compound of the formula (VII) and reacting them under similar conditions.

In the practice of the process (4), the compound of the formula (XIII) is dissolved in an organic solvent such as ethanol and reacted with an equimolar or excessive molar amount of hydrazine, preferably hydrazine hydrate. The reaction is carried out at room temperature or a temperature above it, preferably reflux point of the solvent for 1—4 hours.

Isolation of the product (I) from the reaction mixture can be carried out by pouring the reaction mixture into ice-water, extracting the mixture with an organic solvent such as benzene or chloroform, washing the extract with water, drying the extract and further concentrating it. The product (I) is generally an oil and can be converted to an inorganic acid salt thereof such as hydrochloride and sulfate or an organic acid salt such as oxalate, malonate and succinate.

The compound of the formula (I) obtained according to the invention is a novel compound and is useful as a medicine having tranquilizing activity, antidepressive activity, anti-inflammatory activity, circulatory activity, etc.

The following examples are intended only to illustrate the invention and the invention is not limited by the examples.

#### Experimental Example 1.

##### *Anti-reserpine activity*

ddY Strain male mice (4—5 weeks old, body weight 23—25 g) were intraperitoneally treated with 5 mg/kg of reserpine and after 3 hours the rectal temperatures were determined. Referring to the determined temperatures, the mice were divided into groups of 6 mice each to make the mean temperature of each group as much the same as possible. 4 hours after the administration of reserpine, 100 mg/kg each of the samples was orally administered to the mice. Rectal temperatures were determined 1 hour and 3 hours after the oral administration of the samples and effects of the samples on rectal temperature were calculated as a ratio with the control drug, that is, imipramine, according to the following equation to obtain the values shown in Table 1.

Temperature difference between groups treated with samples and a control group (treated with vehicle)

T=

Temperature difference between a group treated with imipramine and a control group (treated with vehicle)

TABLE 1.

Samples	Anti-reserpine activity
Compound of Example 3	0.7
Compound of Example 7	1.0
Compound of Example 8	0.7
Compound of Example 9	0.7
Compound of Example 10	1.0
Compound of Example 16	0.5
Compound of Example 29	1.0
imipramine	1.0
desipramine	1.0

#### Experimental Example 2.

##### *Barbiturate potentiation*

ddY Strain male mice (4—5 weeks old, body weight 23—28 g) in groups of 5 mice each were orally treated with 100 mg/kg of samples and 30 minutes after the

oral administration the mice were intraperitoneally treated with 100 mg/kg of hexobarbital. Duration of loss of righting reflex due to hexobarbital was determined and barbiturate potentiation ratios with control groups were calculated. The calculated values are given in Table 2. Imipramine, desipramine and diazepam were used as control drugs.

5

5

TABLE 2.

Samples	Barbiturate potentiation
Compound of Example 1	3.0
Compound of Example 2	1.5
Compound of Example 3	1.5
Compound of Example 4	1.2
Compound of Example 6	2.9
Compound of Example 7	1.9
Compound of Example 8	1.3
Compound of Example 10	1.0
Compound of Example 11	1.3
Compound of Example 12	1.0
Compound of Example 14	1.7
Compound of Example 15	1.4
Compound of Example 17	1.0
Compound of Example 19	1.2
Compound of Example 20	1.6
Compound of Example 23	1.3
Compound of Example 25	1.1
Compound of Example 29	1.7
Compound of Example 34	2.5
imipramine	1.3
desipramine	1.5
diazepam*	2.3

\*5 mg/kg was orally administered.

#### Experimental Example 3.

ddY Strain mice and Wistar-Imamichi strain rats were used to inspect acute toxicity and subacute toxicity (30 days; oral administration) of a compound of the formula [I].

10

10

TABLE 3

Sample \ Animal	LD <sub>50</sub> (mg/kg p.o.)		Subacute toxicity
	mouse	rat	rat
Compound of Example 10	♂ 580 ♀ 660	3000~ 5000	not fatal at a dose of 100 mg/kg; no abnormal symptom at this dose.
Imipramine	350	900	not fatal at a dose of 50 mg/kg; At this dose normal increase in body weight is depressed and hemoglobin and blood urine nitrogen are reduced. Marginal part of liver appears dull.

## Example 1.

Dimethylaminoethyl chloride hydrochloride (4.32 g) was dissolved in water (20 ml) and the solution was alkalized by the addition of aqueous sodium hydroxide solution. Then the solution was thoroughly mixed with toluene (30 ml) and the organic layer was dried over sodium sulfate. Separately, 3-phenylindazole (3.88 g) was dissolved in dimethyl formamide (60 ml) and sodium hydride, 50% pure, (1.15 g) was added to the solution, followed by adding dropwise the previously prepared toluene solution. The mixture was heated to 70°C and stirred for 75 min. at that temperature and then poured into ice-water and extracted with chloroform. The extract was washed with water, dried over sodium sulfate and concentrated by evaporation. The residue was treated with ether-hydrochloric acid to form hydrochloride. The product was recrystallized from ethanol-ether to obtain 2.0 g of 1-dimethylaminoethyl-3-phenylindazole hydrochloride (m.p. 163—165°C).

Analysis:

Calcd. for C<sub>17</sub>H<sub>20</sub>N<sub>3</sub>Cl: C, 67.65; H, 6.68; N, 13.92(%)

Found: C, 67.36; H, 6.59; N, 13.72(%)

## Example 2.

By the procedure similar to that described in Example 1, 3-phenyl-5-chloroindazole (4.57 g) and dimethylaminoethyl chloride hydrochloride (4.32 g) were treated to obtain 3.5 g of 1-dimethylaminoethyl-3-phenyl-5-chloroindazole hydrochloride (m.p. 200—201°C).

Analysis:

Calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>Cl: C, 60.72; H, 5.70; N, 12.49(%)

Found: C, 60.99; H, 5.74; N, 12.53(%)

## Example 3.

By the procedure similar to that described in Example 1, 3-phenyl-5-methylindazole (4.17 g) and dimethylaminoethyl chloride hydrochloride (4.32 g) were treated to obtain 4.0 g of 1-dimethylaminoethyl-3-phenyl-5-methylindazole hydrochloride (m.p. 191—192°C).

Analysis:

Calcd. for C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>Cl: C, 68.45; H, 7.02; N, 13.30(%)

Found: C, 68.42; H, 7.17; N, 13.28(%)

## Example 4.

By the procedure similar to that described in Example 1, 3-phenyl-5-chloroindazole (4.57 g) and diethylaminoethyl chloride hydrochloride (5.16 g) were treated to obtain 5.1 g of 1-diethylaminoethyl-3-phenyl-5-chloroindazole hydrochloride (m.p. 185—186°C).

Analysis:

Calcd. for C<sub>19</sub>H<sub>23</sub>N<sub>3</sub>Cl<sub>2</sub>: C, 62.64; H, 6.36; N, 11.54(%)

Found: C, 62.41; H, 6.23; N, 11.33(%)

## Example 5.

By the procedure similar to that described in Example 1, 3-phenyl-5-methylindazole (4.17 g) and diethylaminoethyl chloride hydrochloride (5.16 g) were treated to obtain 4.0 g of 1-diethylaminoethyl-3-phenyl-5-methylindazole hydrochloride (m.p. 131—133°C).

Analysis:

Calcd. for  $C_{20}H_{26}N_3Cl$ : C, 69.85; H, 7.62; N, 12.22 (%)  
Found: C, 69.81; H, 7.59; N, 12.01 (%)

## Example 6.

By the procedure similar to that described in Example 1, 3-phenylindazole (3.88 g) and diethylaminoethyl chloride hydrochloride (5.16 g) were treated to obtain 2.0 g of 1-diethylaminoethyl-3-phenylindazole hydrochloride (m.p. 114—118°C).

Analysis:

Calcd. for  $C_{19}H_{24}N_3Cl \cdot H_2O$ : C, 65.60; H, 7.53; N, 12.08 (%)  
Found: C, 65.16; H, 7.25; N, 11.79 (%)

## Example 7.

By the procedure similar to that described in Example 1, 3-phenylindazole (3.88 g) and dimethylaminopropyl chloride hydrochloride (4.74 g) to obtain 3.5 g of 1-dimethylaminopropyl-3-phenylindazole hydrochloride (m.p. 140—143°C).

Analysis:

Calcd. for  $C_{18}H_{23}N_3Cl \cdot 2H_2O$ : C, 61.44; H, 7.44; N, 11.94 (%)  
Found: C, 61.04; H, 7.55; N, 11.72 (%)

## Example 8.

By the procedure similar to that described in Example 1, 3-phenyl-5-chloroindazole (4.57 g) and dimethylaminopropyl chloride hydrochloride (4.74 g) were treated to obtain 4.74 g of 1-dimethylaminopropyl-3-phenyl-5-chloroindazole hydrochloride (m.p. 158—160°C).

Analysis:

Calcd. for  $C_{18}H_{21}N_3Cl_2$ : C, 61.72; H, 6.04; N, 12.00 (%)  
Found: C, 61.47; H, 5.95; N, 11.71 (%)

## Example 9.

By the procedure similar to that described in Example 1, 3-phenyl-5-bromoindazole (4.10 g) and dimethylaminopropyl chloride hydrochloride (3.56 g) were treated to obtain 4.0 g of 1-dimethylaminopropyl-3-phenyl-5-bromoindazole hydrochloride (m.p. 149—150°C).

Analysis:

Calcd. for  $C_{18}H_{21}N_3ClBr$ : C, 54.77; H, 5.36; N, 10.65 (%)  
Found: C, 54.35; H, 5.46; N, 10.17 (%)

## Example 10.

By the procedure similar to that described in Example 1, 3-phenyl-5-methylindazole (4.17 g) and dimethylaminopropyl chloride hydrochloride (4.74 g) were treated to obtain an oily product. The product was purified through distillation under reduced pressure to obtain 3.5 g of 1-dimethylaminopropyl-3-phenyl-5-methylindazole (b.p. 185°C/0.5 mmHg).

Analysis:

Calcd. for  $C_{19}H_{23}N_3$ : C, 77.78; H, 7.90; N, 14.32 (%)  
Found: C, 77.68; H, 7.85; N, 14.11 (%)

The resulting oily product was reacted with oxalic acid to obtain 3.4 g of 1-dimethylaminopropyl-3-phenyl-5-methylindazole oxalate (m.p. 184—185°C).

Analysis:

Calcd. for  $C_{21}H_{25}N_3O_4$ : C, 65.78; H, 6.57; N, 10.96 (%)  
Found: C, 65.53; H, 6.58; N, 10.82 (%)

1-Dimethylaminopropyl-3-phenyl-5-methylindazole was converted by a conventional way to its hydrochloride having a melting point between 139—140°C.

Analysis:

Calcd. for  $C_{19}H_{24}N_3Cl$ : C, 69.18; H, 7.33; N, 12.74 (%)  
Found: C, 69.01; H, 7.28; N, 12.68 (%)



## Example 11.

By the procedure similar to that described in Example 1, 3-phenylindazole (3.88 g) and piperidinopropyl chloride hydrochloride (5.94 g) were treated to obtain 5.3 g of 1-piperidinopropyl-3-phenylindazole hydrochloride (m.p. 201—202°C).

Analysis:

Calcd. for  $C_{21}H_{26}N_3Cl$ :

C, 70.87; H, 7.36; N, 11.81 (%)

Found:

C, 71.11; H, 7.39; N, 11.89 (%)

## Example 12.

By the procedure similar to that described in Example 1, 3-phenyl-5-methylindazole (4.17 g) and piperidinopropyl chloride hydrochloride were treated to obtain 5.0 g of 1-piperidinopropyl-3-phenyl-5-methylindazole hydrochloride (m.p. 222—223°C).

Analysis:

Calcd. for  $C_{22}H_{28}N_3Cl$ :

C, 71.43; H, 7.63; N, 11.36 (%)

Found:

C, 71.50; H, 7.61; N, 11.47 (%)

## Example 13.

3-Phenyl-5-methylindazole (4.17 g) was dissolved in dimethylformamide (70 ml) and sodium hydride 50% pure (1.15 g) was added to the solution, followed by stirring it at room temperature for 10 min. To the resulting solution was added dropwise a solution of diethylaminopropyl chloride (3.59 g) in 30 ml of toluene. The mixture was stirred at 70°C for 1 hour and poured into ice-water, and extracted with chloroform. The extract was washed with water, dried over sodium sulfate and concentrated by evaporation. The residue was treated with ether-hydrochloric acid to obtain 4.5 g of 1-diethylaminopropyl-3-phenyl-5-methylindazole hydrochloride (m.p. 127—129°C).

Analysis:

Calcd. for  $C_{21}H_{28}N_3Cl$ :

C, 70.47; H, 7.89; N, 11.74 (%)

Found:

C, 70.24; H, 8.26; N, 11.28 (%)

## Example 14.

By the procedure similar to that described in Example 13, 3-phenyl-5-chloroindazole (4.57 g) and morpholinoethyl chloride (3.59 g) were treated to obtain 3.7 g of 1-morpholinoethyl-3-phenyl-5-chloroindazole hydrochloride (m.p. 226—229°C).

Analysis:

Calcd. for  $C_{19}H_{21}N_3OCl_2$ :

C, 60.32; H, 5.60; N, 11.11 (%)

Found:

C, 60.55; H, 5.59; N, 11.22 (%)

## Example 15.

By the procedure similar to that described in Example 13, 3-phenyl-5-methylindazole (4.17 g) and 1-morpholinopropyl chloride (3.93 g) were treated to obtain 4.1 g of 1-morpholinopropyl-3-phenyl-5-methylindazole hydrochloride (m.p. 180—182°C).

Analysis:

Calcd. for  $C_{21}H_{28}N_3OCl$ :

C, 67.82; H, 7.05; N, 11.30 (%)

Found:

C, 67.89; H, 6.85; N, 11.36 (%)

## Example 16.

By the procedure similar to that described in Example 13, 3-phenylindazole (3.88 g) and N-methylpiperazinopropyl chloride (4.24 g) were treated to obtain 6.8 g of 1-N-methylpiperazinopropyl-3-phenyl indazole hydrochloride (m.p. 222—224°C).

Analysis:

Calcd. for  $C_{21}H_{28}N_4Cl_2 \cdot H_2O$ :

C, 59.29; H, 7.11; N, 13.17 (%)

Found:

C, 59.54; H, 7.02; N, 13.23 (%)

## Example 17.

By the procedure similar to that described in Example 13, 3-phenyl-5-methylindazole (4.17 g) and N-methylpiperazinopropyl chloride (4.24 g) were treated to obtain 4.0 g of 1-N-methylpiperazinopropyl-3-phenyl-5-methylindazole hydrochloride (m.p. 226—228°C).

## Analysis:

Calcd. for  $C_{22}H_{30}N_4Cl_2 \cdot 1/2 H_2O$ : C, 61.39; H, 7.25; N, 13.02 (%)

Found: C, 61.10; H, 7.01; N, 13.05 (%)

## Example 18.

5 By the procedure similar to that described in Example 13, 3-phenyl-5-methylindazole (4.17 g) and diallylaminopropyl chloride (4.17 g) were treated to obtain 5  
4.3 g of 1-diallylaminopropyl-3-phenyl-5-methylindazole hydrochloride (m.p. 81—82°C).

## Analysis:

10 Calcd. for  $C_{23}H_{28}N_4Cl$ : C, 72.33; H, 7.39; N, 11.00 (%) 10

Found: C, 72.74; H, 7.88; N, 11.07 (%)

## Example 19.

15 (a) 3-Phenyl-5-chloroindazole (2.29 g), paraformaldehyde (0.35 g), morpholine (1.91 g) and 1N aqueous sodium hydroxide solution (1 ml) were added to 40 ml of 15  
ethanol and the mixture was allowed to react under reflux. The reaction mixture was concentrated and then the residue was dissolved in chloroform, washed with water, dried over sodium sulfate and concentrated. The residue was treated with column chromatography to obtain 1.7 g of 1-morpholinomethyl-3-phenyl-5-chloroindazole having a melting point of between 155—156° after recrystallization from 20  
methanol.

## Analysis:

Calcd. for  $C_{18}H_{18}N_2OCl$ : C, 65.95; H, 5.53; N, 12.82 (%)

Found: C, 65.63; H, 5.44; N, 12.69 (%)

25 (b) 3-Phenyl-5-chloroindazole (9.16 g), paraformaldehyde (1.5 g), and 5% 25  
aqueous sodium hydroxide solution (1 ml) were added to ethanol (40 ml) and the mixture was heated under reflux for 3 hours. After cooling the mixture, the precipitated crystals were recovered by filtration to obtain 8.0 g of 1-hydroxymethyl-3-phenyl-5-chloroindazole (m.p. 144—146°C).

30 Analysis: 30

Calcd. for  $C_{14}H_{11}N_2OCl$ : C, 65.00; H, 4.29; N, 10.83 (%)

Found: C, 65.21; H, 4.32; N, 10.71 (%)

35 The product obtained above and morpholine were treated by a procedure similar to that described in (a) of Example 19 to obtain the same product as 35  
produced in (a) of Example 19.

## Example 20.

40 By the procedure similar to that described in Example 19, 3-phenyl-5-methylindazole (3.13 g), paraformaldehyde (0.53 g) and pyrrolidine (2.1 g) were treated 40  
to obtain an oily product. The product was treated with ether-hydrochloric acid to produce 3.8 g of 1-pyrrolidino-methyl-3-phenyl-5-methylindazole hydrochloride having a melting point between 161—162°C after recrystallization from ethanol-ether.

## Analysis:

45 Calcd. for  $C_{19}H_{22}N_3Cl$ : C, 69.61; H, 6.76; N, 12.82 (%) 45

Found: C, 69.37; H, 6.69; N, 12.99 (%)

## Example 21.

50 (a) By the procedure similar to that described in Example 19, 3-phenylindazole (2.91 g), paraformaldehyde (0.50 g) and N-phenylpiperazine (4.87 g) were treated to 50  
obtain 4.3 g of 1-N-phenylpiperazinomethyl-3-phenylindazole having a melting point between 109—110°C after recrystallization from ethanol.

## Analysis:

Calcd. for  $C_{24}H_{24}N_4$ : C, 78.23; H, 6.57; N, 15.21 (%)

Found: C, 78.39; H, 6.42; N, 15.31 (%)

55 (b) 3-Phenylindazole (9.71 g), paraformaldehyde (2.25 g) and 5% aqueous sodium hydroxide solution (1 ml) were added to ethanol (40 ml) and the mixture was 55  
heated under reflux for 3 hours. After cooling the reaction mixture, the precipitated crystals were recovered by filtration to obtain 8.7 g of 1-

hydroxymethyl-3-phenylindazole having a melting point between 103—105°C after recrystallization from ligroine.

Analysis:

Calcd. for  $C_{14}H_{12}N_2O$ : C, 74.98; N, 5.39; N, 12.49 (%)  
Found: C, 74.92; H, 5.18; N, 12.61 (%)

1-Hydroxymethyl-3-phenylindazole obtained above and N-phenylpiperazine were treated by a procedure similar to that described in (a) of Example 19 to obtain the same product as produced in (a) of Example 22.

#### Example 22.

(a) By the procedure similar to that described in Example 19, 3-phenyl-5-methylindazole (2.08 g), paraformaldehyde (0.35 g) and 2-(4'-chlorophenyl)-1,2,3,6-tetrahydro-4-methylpyridine (4.0 g) were treated to obtain 2.8 g of 1-[2'-(4''-chlorophenyl)-1',2',3',6'-tetrahydro-4'-methyl]-pyridinomethyl-3-phenyl-5-methylindazole (m.p. 130—131°C).

Analysis:

Calcd. for  $C_{27}H_{28}N_3Cl$ : C, 75.77; H, 6.12; N, 9.82 (%)  
Found: C, 76.19; H, 6.13; N, 10.28 (%)

(b) By the procedure similar to that described in Example 19, 3-phenyl-5-methylindazole (13.7 g) and paraformaldehyde (2.4 g) were treated to obtain 13.1 g of 1-hydroxy-3-phenyl-5-methylindazole (m.p. 109—111°C).

Analysis:

Calcd. for  $C_{15}H_{14}N_2O$ : C, 75.61; H, 5.92; N, 11.76 (%)  
Found: C, 75.54; H, 5.82; N, 11.76 (%)

1-Hydroxymethyl-3-phenyl-5-methylindazole obtained above and 2-(4'-chlorophenyl)-1,2,3,6-tetrahydro-4-methylpyridine were treated by a procedure similar to that described in (a) of Example 19 to obtain the same product as produced in (a) of Example 22.

#### Example 23.

1-Hydroxymethyl-3-phenylindazole (2 g), morpholine (0.84 g) and 5% aqueous sodium hydroxide solution (1 ml) were dissolved in ethanol (30 ml), and the mixture was heated under reflux for 3 hours. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting oily residue was treated with ether-hydrochloric acid to obtain 1-morpholinomethyl-3-phenylindazole having a melting point between 166—167°C (decomposition) after recrystallization from ethanol-ether.

Analysis:

Calcd. for  $C_{18}H_{20}N_2OCl$ : C, 65.55; H, 6.11; N, 12.74 (%)  
Found: C, 65.48; H, 6.26; N, 12.58 (%)

#### Example 24.

3-Phenyl-5-methylindazole (4.17 g) was dissolved in dimethylformamide (70 ml) and to the solution was added sodium hydride 50% pure (0.96 g) followed by stirring at room temperature for 10 minutes. To the resulting mixture was added a solution of phthalimidopropyl chloride (4.47 g) in dimethylformamide (50 ml) followed by stirring at 95°C for 6 hours. The reaction mixture was poured into ice-water and then extracted with chloroform. The extract was washed with water, dried over sodium sulfate and concentrated under reduced pressure to obtain 4.9 g of 1-phthalimidopropyl-3-phenyl-5-methylindazole having a melting point between 131—132°C after recrystallization from methanol.

Analysis:

Calcd. for  $C_{25}H_{21}N_3O_2$ : C, 75.93; H, 5.35; N, 10.63 (%)  
Found: C, 75.96; H, 5.27; N, 10.61 (%)

#### Example 25.

By the procedure similar to that described in Example 24, 3-phenyl-5-chloroindazole (9.2 g), sodium hydride 50% pure (2.3 g) and phthalimidopropyl chloride (9.0 g) were treated to obtain 10.4 g of 1-phthalimidopropyl-3-phenyl-5-chloroindazole. Recrystallization from methanol gave a product having a melting point between 121—122°C.

## Analysis:

Calcd. for  $C_{24}H_{18}N_3O_2Cl$ : C, 69.31; H, 4.36; N, 10.10 (%)  
 Found: C, 69.33; H, 4.43; N, 10.34 (%)

## Example 26.

5 By the procedure similar to that described in Example 24, 3-phenylindazole (7.76 g), sodium hydride 50% pure (2.3 g) and phthalimidopropyl chloride (9.0 g) were treated to obtain 8.0 g of 1-phthalimidopropyl-3-phenylindazole having a melting point between 129—130°C after recrystallization from methanol.

## Analysis:

10 Calcd. for  $C_{24}H_{19}N_3O_2$ : C, 75.57; H, 5.02; N, 11.02 (%)  
 Found: C, 75.57; H, 4.99; N, 11.10 (%)

## Example 27.

15 1-N-Monomethylcarbamoyl-3-phenylindazole (m.p. 111—112°C) (50 g) was dissolved in anhydrous tetrahydrofuran (40 ml) and to the solution was added lithium aluminum hydride (1.5 g) under cooling with ice followed by heating under reflux for 20 min. while stirring. Aqueous ether and aqueous sodium hydroxide solution were added to the resulting reaction mixture to separate an organic layer. 10% Hydrochloric acid was added to the organic layer to separate water layer. The water layer was alkalinized with the addition of an aqueous sodium hydroxide solution, extracted with benzene, and the extract was washed with water, dried over sodium sulfate and concentrated under reduced pressure to obtain 1.2 g of 1-N-monomethylaminopropyl-3-phenylindazole as an oily product. The product was converted to its oxalate by a conventional way and then recrystallized from methanol to obtain crystals having a melting point between 197—198°C (decomposition).

## Analysis:

25 Calcd. for  $C_{19}H_{21}N_3O_4$ : C, 64.21; H, 5.91; N, 11.82 (%)  
 Found: C, 64.26; H, 5.95; N, 11.97 (%)

## Example 28.

30 By the procedure similar to that described in Example 27, 1-N-monomethylcarbamoyl-3-phenyl-5-chloroindazole (m.p. 123—125°C) (5.0 g) was treated with the use of lithium aluminum hydride (1.5 g) to obtain 2.0 g of 1-N-monomethylaminopropyl-3-phenyl-5-chloroindazole oxalate having a melting point between 203—204°C (decomposition) after recrystallization from ethanol.

## Analysis:

35 Calcd. for  $C_{19}H_{20}N_3O_4Cl$ : C, 58.54; H, 5.17; N, 10.78 (%)  
 Found: C, 58.89; H, 5.16; N, 10.58 (%)

## Example 29.

40 By the procedure similar to that described in Example 27, 1-N-monomethylcarbamoyl-3-phenyl-5-methylindazole (m.p. 128—130°C) (5.0 g) was treated with the use of lithium aluminum hydride (1.5 g) to obtain 1.8 g of 1-N-monomethylaminopropyl-3-phenyl-5-methylindazole hydrochloride having a melting point between 148—149°C after recrystallization from ethanol-ether.

## Analysis:

45 Calcd. for  $C_{19}H_{22}N_3Cl$ : C, 68.45; H, 7.02; N, 13.30 (%)  
 Found: C, 68.70; H, 7.05; N, 13.35 (%)

## Example 30.

50 Oily 1-N-phenylpiperazinocarbonyl-3-phenyl-5-methylindazole (4.0 g) which had been prepared by reacting in order 1-hydroxycarbonyl-3-phenyl-5-methylindazole with ethyl chlorocarbonate and N-phenylpiperazine was treated with the use of lithium aluminum hydride (1.2 g) by the procedure similar to that described in Example 27 to obtain 6.1 g of 1-N-phenylpiperazinopropyl-3-phenyl-5-methylindazole hydrochloride having a melting point between 195—200°C after recrystallization from ethanol-ether.

## Analysis:

55 Calcd. for  $C_{27}H_{30}N_4.HCl$ : C, 72.55; H, 6.99; N, 12.53 (%)  
 Found: C, 72.46; H, 7.02; N, 12.57 (%)

## Example 31.

By the procedure similar to that described in Example 27, 1-N,N-dimethyl-

carbamoyl-ethyl-3-phenyl-5-methylindazole (m.p. 99—100°C) (5.0 g) was treated with the use of lithium aluminum hydride (1.5 g) to obtain 1.9 g of 1-N,N-dimethylaminopropyl-3-phenyl-5-methylindazole oxalate having a melting point between 184—185°C after recrystallization from ethanol.

Analysis:

Calcd. for  $C_{21}H_{23}N_3O_4$ : C, 65.78; H, 6.57; N, 10.96 (%)  
 Found: C, 65.70; H, 6.61; N, 10.82 (%)

#### Example 32.

By the procedure similar to that described in Example 27, 1-carbamoyl-ethyl-3-phenyl-5-chloroindazole (m.p. 156—157°C) (5.0 g) was treated with the use of lithium aluminum hydride (1.5 g) to obtain 2.0 g of 1-aminopropyl-3-phenyl-5-chloroindazole hydrochloride having a melting point between 163—164°C after recrystallization from ethanol-ether.

Analysis:

Calcd. for  $C_{16}H_{17}N_3Cl_2$ : C, 59.64; H, 5.32; N, 13.04 (%)  
 Found: C, 59.65; H, 5.42; N, 13.20 (%)

#### Example 33.

1-Phthalimidopropyl-3-phenyl-5-chloroindazole (8.3 g) and hydrazine hydrate (2.0 g) were added to ethanol (150 ml) followed by heating under reflux for 3 hours. The reaction mixture was concentrated under reduced pressure and to the residue were added benzene (150 ml) and 10% aqueous sodium hydroxide solution (200 ml) followed by stirring at room temperature for 1 hour. The organic layer was separated from the mixture and it was washed with water, dried over sodium sulfate and concentrated under reduced pressure to obtain 5.5 g of 1-aminopropyl-3-phenyl-5-chloroindazole as an oily product. The product was treated with ether-hydrochloric acid to form its hydrochloride. After recrystallization from ethanol-ether, the product had a melting point between 163—164°C.

Analysis:

Calcd. for  $C_{16}H_{17}N_3Cl_2$ : C, 59.64; H, 5.32; N, 13.04 (%)  
 Found: C, 59.75; H, 5.28; N, 13.19 (%)

#### Example 34.

By the procedure similar to that described in Example 33, 1-phthalimidopropyl-3-phenyl-5-methylindazole (5.0 g) and hydrazine hydrate (1.5 g) were treated to obtain 3.1 g of 1-aminopropyl-3-phenyl-5-methylindazole as an oily product. The product was converted by a conventional way to its hydrochloride having a melting point between 161—163°C.

Analysis:

Calcd. for  $C_{17}H_{20}N_3Cl$ : C, 67.65; H, 6.68; N, 13.92 (%)  
 Found: C, 67.64; H, 6.76; N, 13.63 (%)

#### Example 35.

By the procedure similar to that described in Example 33, 1-phthalimidopropyl-3-phenylindazole (6.0 g) and hydrazine hydrate (2.0 g) were treated to obtain 3.8 g of 1-aminopropyl-3-phenylindazole as an oily product. Infrared Absorption Spectra: (neat) ( $cm^{-1}$ )

3370, 3050, 2930, 2870,  
 1615, 1605, 1495, 1150,  
 778, 750, 695

NMR:  $\delta(CDCl_3)$

1.57 ( $-NH_2$ , 2H)  
 2.06 ( $-C-CH_2-C-$ , 2H, quintet)  
 2.73 ( $-CH_2NH_2$ , 2H, triplet)

4.52 ( $\begin{array}{c} \diagup \\ N \\ \diagdown \end{array}$ , 2H, triplet)  
 $\begin{array}{c} CH_2-CH_2- \end{array}$

7.0—8.1 (aromatic proton, 9H)

## Example 36.

3-Phenyl-5-fluorindazole (2.12 g), paraformaldehyde (0.33 g), piperidine (1 g) and 1N aqueous sodium hydroxide solution (1 ml) were added to ethanol (30 ml) followed by heating under reflux for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in benzene, washed with water, dried over sodium sulfate and concentrated under reduced pressure to obtain 1.9 g of 1-piperidinomethyl-3-phenyl-5-fluorindazole having a melting point between 82—84°C after recrystallization from methanol.

Analysis:

Calcd. for  $C_{19}H_{20}N_3F$ : C, 73.76; H, 6.52; N, 13.58 (%)

Found: C, 73.94; H, 6.46; N, 13.83 (%)

## Example 37.

3-Phenyl-5-chloroindazole (4.57 g), piperidinoethyl chloride (3.6 g), and triethylbenzylammonium chloride (0.5 g) were added to 50% aqueous sodium hydroxide solution (5 ml) followed by stirring at 70°C for 1 hour. After completion of the reaction, the mixture was extracted with benzene and the extract was washed with water, dried over sodium sulfate and concentrated. The residue was treated with ethanol-hydrochloric acid to obtain 4.3 g of 1-piperidinoethyl-3-phenyl-5-chloroindazole hydrochloride having a melting point between 230—235°C after recrystallization from acetone.

Analysis:

Calcd. for  $C_{20}H_{23}N_3Cl_2$ : C, 63.83; H, 6.16; N, 11.17 (%)

Found: C, 64.26; H, 6.19; N, 11.34 (%)

## Example 38.

By the procedure similar to that described in Example 27, 1-N-mono(n-butyl)-carbamoyl-3-phenylindazole (3.5 g) was treated with the use of lithium aluminum hydride (1.0 g) to obtain 0.3 g of 1-n-butylaminopropyl-3-phenylindazole as an oily product. The product was converted to its oxalate which had a melting point of 181—183°C after recrystallization from methanol.

Analysis:

Calcd. for  $C_{22}H_{27}N_3O_4$ : C, 66.48; H, 6.85; N, 10.57 (%)

Found: C, 66.31; H, 6.90; N, 11.66 (%)

## Example 39.

By the procedure similar to that described in Example 27, 1-N-monoallyl-carbamoyl-3-phenylindazole (3.5 g) was treated with the use of lithium aluminum hydride (1.0 g) to obtain 0.9 g of 1-monoallylaminopropyl-3-phenylindazole as an oily product. The product was converted to its oxalate which had a melting point of 203°C after recrystallization from methanol.


Analysis:

Calcd. for  $C_{21}H_{23}N_3O_4$ : C, 66.13; H, 6.08; N, 11.02 (%)

Found: C, 66.19; H, 6.08; N, 11.12 (%)


## WHAT WE CLAIM IS:—

1. An indazole derivative having the formula:




wherein X is a hydrogen atom, a halogen atom or a lower alkyl group; each of R and R' is a hydrogen atom, a lower alkyl group or a lower alkenyl group, or R and R', together with the nitrogen atom to which they are attached, form an unsubstituted or substituted heterocyclic ring; and n is 1, 2 or 3.

2. An indazole having the formula:




wherein X is a hydrogen atom, a halogen atom or a lower alkyl group; each of R and R' is a lower alkyl group or an allyl group, or R and R', together with the nitrogen atom to which they are attached, form a heterocyclic ring optionally substituted by a lower alkyl group; and n is 2 or 3.

3. An indazole derivative having the formula:




wherein X is a hydrogen atom, a halogen atom or a lower alkyl group; each of R and R' is a lower alkyl group, or R and R', together with the nitrogen atom to which they are attached, form an unsubstituted or substituted heterocyclic ring.

4. An indazole derivative having the formula:




wherein X is a hydrogen atom, a halogen atom or a lower alkyl group; and n is 1, 2 or 3.

5. An indazole derivative having the formula:



wherein X is a hydrogen atom, a halogen atom or a lower alkyl group; and n is 1, 2 or 3.

6. An indazole derivative having the formula:



wherein X is a hydrogen atom, a halogen atom or a lower alkyl group; each of R and R' is a hydrogen atom or a lower alkyl group, or R and R', together with the nitrogen atom to which they are attached, form a heterocyclic ring optionally substituted by a phenyl group; and n is 2 or 3.

7. 1-Dimethylaminoethyl-3-phenylindazole.

8. 1-Dimethylaminoethyl-3-phenyl-5-chloroindazole.

9. 1-Dimethylaminoethyl-3-phenyl-5-methylindazole.

10. 1-Diethylaminoethyl-3-phenyl-5-chloroindazole.

11. 1-Diethylaminoethyl-3-phenyl-5-methylindazole.

12. 1-Diethylaminoethyl-3-phenylindazole.

13. 1-Dimethylaminopropyl-3-phenylindazole.

14. 1-Dimethylaminopropyl-3-phenyl-5-chloroindazole.

15. 1-Dimethylaminopropyl-3-phenyl-5-bromoindazole.

16. 1-Dimethylaminopropyl-3-phenyl-5-methylindazole.

17. 1-Piperidinopropyl-3-phenylindazole.


18. 1-Piperidinopropyl-3-phenyl-5-methylindazole.

19. 1-Dimethylaminopropyl-3-phenyl-5-methylindazole.


20. 1-Morpholinoethyl-3-phenyl-5-chloroindazole.

21. 1-Morpholinopropyl-3-phenyl-5-methylindazole.

22. 1-N-methylpiperazinopropyl-3-phenylindazole.  
 23. 1-N-methylpiperazinopropyl-3-phenyl-5-methylindazole.  
 24. 1-Diallylaminopropyl-3-phenyl-5-methylindazole.  
 25. 1-Morpholinomethyl-3-phenyl-5-chloroindazole.  
 5 26. 1-Pyrrolidinomethyl-3-phenyl-5-methylindazole. 5  
 27. 1-N-phenylpiperazinomethyl-3-phenylindazole.  
 28. 1 - [2' - (4'' - chlorophenyl) - 1',2',3',6' - tetrahydro - 4' - methyl]-  
 pyridinomethyl - 3 - phenyl - 5 - methylindazole.  
 29. 2-Morpholinomethyl-3-phenylindazole.  
 10 30. 1-Phthalimidopropyl-3-phenyl-5-methylindazole. 10  
 31. 1-Phthalimidopropyl-3-phenyl-5-chloroindazole.  
 32. 1-Phthalimidopropyl-3-phenylindazole.  
 33. 1-N-monomethylaminopropyl-3-phenylindazole.  
 34. 1-N-monomethylaminopropyl-3-phenyl-5-chloroindazole.  
 15 35. 1-N-monomethylaminopropyl-3-phenyl-5-methylindazole. 15  
 36. 1-N-phenylpiperazinopropyl-3-phenyl-5-methylindazole.  
 37. 1-Aminopropyl-3-phenyl-5-chloroindazole.  
 38. 1-Aminopropyl-3-phenyl-5-methylindazole.  
 39. 1-Aminopropyl-3-phenylindazole.  
 20 40. 1-Piperidinomethyl-3-phenyl-5-fluoroindazole. 20  
 41. 1-Piperidinoethyl-3-phenyl-5-chloroindazole.  
 42. 1-Mono-n-butylaminopropyl-3-phenylindazole.  
 43. 1-Monoallylaminopropyl-3-phenylindazole.  
 44. A process for preparing an indazole derivative as claimed in claim 2, which  
 25 comprises reacting a compound having the formula 25




wherein X is as defined in claim 2, with a compound having the formula



wherein X is a halogen atom, and R, R' and n are as defined in claim 2.


- 30 45. A process for preparing an indazole derivative as claimed in claim 3, which 30  
 comprises reacting a compound having the formula:



wherein X is as defined in claim 3, with a compound having the formula




- 35 46. A process for preparing an indazole derivative as claimed in claim 4, which 35  
 comprises reacting a compound having the formula:




wherein X is as defined in claim 4, with a compound having the formula:






wherein X' is a halogen atom and  $n$  is as defined in claim 4.

47. A process for preparing an indazole derivative as claimed in claim 5, which comprises reacting a compound having the formula:



wherein X and  $n$  are as defined in claim 5, with hydrazine.

48. A process for preparing an indazole derivative as claimed in claim 6, which comprises reducing a compound having the formula:



wherein  $n'$  is  $n-1$ ,  $n$  being as defined in claim 6, and X, R and R' are as defined in claim 6.

49. A process for preparing an indazole derivative as claimed in claim 1, substantially as hereinbefore described.

50. A process for preparing an indazole derivative as claimed in claim 1, substantially as described in any of the foregoing Examples.

51. An indazole derivative whenever prepared by a process as claimed in any of claims 44 to 50.

52. A pharmaceutical composition comprising, as active ingredient, an indazole derivative as claimed in any of claims 1 to 43 and 51, and a pharmaceutically-acceptable diluent or carrier therefor.

HASELTINE, LAKE & CO.,

Chartered Patent Agents,

28 Southampton Buildings,

Chancery Lane,

London WC2A 1AT,

and

Temple Gate House, Temple Gate,

Bristol BS1 6PT

and

9 Park Square, Leeds LS1 2LH.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**